Print

Avinger, Inc. Completes Enrollment of PAD-Focused CONNECT II Global Clinical Trial  
6/12/2012 10:37:58 AM

REDWOOD CITY, Calif.--(BUSINESS WIRE)--Avinger, Inc., a medical device manufacturer of innovative, multi-functional catheters for treating patients with peripheral artery disease (PAD), announced that it has successfully completed enrollment in its CONNECT II global clinical trial. PAD is a silent epidemic that affects 8 to 12 million adults in the U.S., 30 million globally and is the leading cause of amputation in patients over 50. A study published in the January 2012 American Heart Association journal Circulation claims that PAD is an unsung “pandemic” that afflicts even more women than men.
//-->